Medrx Co

Medrx Co Accounts Payable

The Accounts Payable of Medrx Co (4586.T) as of Nov 19, 2026 is 80.85 M JPY. In the previous year, Accounts Payable was 88.89 M JPY — a change of -9.04% (lower).

Accounts Payable

80.85 MJPY

YoY

-9.04%

Last updated:

Accounts Payable of Medrx Co is 2021 80.85 M JPY. Accounts Payable of Medrx Co was 2020 88.89 M JPY. It decreases by -9.04% lower compared to the previous year.

The Medrx Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2014
402,000.00 JPY
Jan 1, 2015
962,000.00 JPY
Jan 1, 2016
108,000.00 JPY
Jan 1, 2018
58,000.00 JPY
Jan 1, 2019
74.51 M JPY
Jan 1, 2020
88.89 M JPY
Jan 1, 2021
80.85 M JPY
The Medrx Co Accounts Payable history
YEARAccounts PayableYoY
80.85 MJPY-9.04%
88.89 MJPY+19.30%
74.51 MJPY+128,358.62%
58,000.00JPY-46.30%
108,000.00JPY-88.77%
962,000.00JPY+139.30%
402,000.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Accounts Payable of Medrx Co is 80.85 M JPY in 2021.

Accounts Payable of Medrx Co changed from 88.89 M JPY to 80.85 M JPY, representing a -9.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medrx Co

All Key Metrics — Medrx Co